Ajovy®

Active substance

fremanezumab

Holder

Teva Pharma Belgium N.V./S.A.

Status

Closed

Public documents

Prophylaxis of migraine in adult patients who suffer from at least 8 monthly migraine days and who previously failed on at least 3 preventive treatment classes and cannot be satisfactorily treated with the other approved and commercially available alternative treatments, in accordance with clinical guidelines, because of efficacy and/or safety issues.

Public documents

Approbation

Information for the patient

Informed consent

Last update

16/02/2021